Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2016 | Pages:
734 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2016', provides an overview of the Diffuse Large B-Cell Lymphoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diffuse Large B-Cell Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diffuse Large B-Cell Lymphoma and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Diffuse Large B-Cell Lymphoma - The report reviews pipeline therapeutics for Diffuse Large B-Cell Lymphoma by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Diffuse Large B-Cell Lymphoma therapeutics and enlists all their major and minor projects - The report assesses Diffuse Large B-Cell Lymphoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Diffuse Large B-Cell Lymphoma Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Diffuse Large B-Cell Lymphoma - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Diffuse Large B-Cell Lymphoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 Introduction 6 Diffuse Large B-Cell Lymphoma Overview 7 Therapeutics Development 8 Diffuse Large B-Cell Lymphoma - Therapeutics under Development by Companies 10 Diffuse Large B-Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes 15 Diffuse Large B-Cell Lymphoma - Pipeline Products Glance 16 Diffuse Large B-Cell Lymphoma - Products under Development by Companies 19 Diffuse Large B-Cell Lymphoma - Products under Investigation by Universities/Institutes 27 Diffuse Large B-Cell Lymphoma - Companies Involved in Therapeutics Development 28 Diffuse Large B-Cell Lymphoma - Therapeutics Assessment 99 Drug Profiles 114 Diffuse Large B-Cell Lymphoma - Recent Pipeline Updates 413 Diffuse Large B-Cell Lymphoma - Dormant Projects 708 Diffuse Large B-Cell Lymphoma - Dormant Projects 708 Diffuse Large B-Cell Lymphoma - Discontinued Products 711 Diffuse Large B-Cell Lymphoma - Product Development Milestones 713 Appendix 719
List of Tables
Number of Products under Development for Diffuse Large B-Cell Lymphoma, H1 2016 22 Number of Products under Development for Diffuse Large B-Cell Lymphoma - Comparative Analysis, H1 2016 23 Number of Products under Development by Companies, H1 2016 24 Number of Products under Development by Companies, H1 2016 (Contd..1) 25 Number of Products under Development by Companies, H1 2016 (Contd..2) 26 Number of Products under Development by Companies, H1 2016 (Contd..3) 27 Number of Products under Development by Companies, H1 2016 (Contd..4) 28 Number of Products under Investigation by Universities/Institutes, H1 2016 29 Comparative Analysis by Late Stage Development, H1 2016 30 Comparative Analysis by Clinical Stage Development, H1 2016 31 Comparative Analysis by Early Stage Development, H1 2016 32 Products under Development by Companies, H1 2016 33 Products under Development by Companies, H1 2016 (Contd..1) 34 Products under Development by Companies, H1 2016 (Contd..2) 35 Products under Development by Companies, H1 2016 (Contd..3) 36 Products under Development by Companies, H1 2016 (Contd..4) 37 Products under Development by Companies, H1 2016 (Contd..5) 38 Products under Development by Companies, H1 2016 (Contd..6) 39 Products under Development by Companies, H1 2016 (Contd..7) 40 Products under Investigation by Universities/Institutes, H1 2016 41 Diffuse Large B-Cell Lymphoma - Pipeline by AbbVie Inc., H1 2016 42 Diffuse Large B-Cell Lymphoma - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016 43 Diffuse Large B-Cell Lymphoma - Pipeline by Affimed GmbH , H1 2016 44 Diffuse Large B-Cell Lymphoma - Pipeline by Amgen Inc., H1 2016 45 Diffuse Large B-Cell Lymphoma - Pipeline by Ariad Pharmaceuticals, Inc., H1 2016 46 Diffuse Large B-Cell Lymphoma - Pipeline by Arrien Pharmaceuticals, LLC, H1 2016 47 Diffuse Large B-Cell Lymphoma - Pipeline by Astellas Pharma Inc., H1 2016 48 Diffuse Large B-Cell Lymphoma - Pipeline by AstraZeneca Plc, H1 2016 49 Diffuse Large B-Cell Lymphoma - Pipeline by Aurigene Discovery Technologies Limited, H1 2016 50 Diffuse Large B-Cell Lymphoma - Pipeline by Bayer AG, H1 2016 51 Diffuse Large B-Cell Lymphoma - Pipeline by BeiGene, Ltd., H1 2016 52 Diffuse Large B-Cell Lymphoma - Pipeline by BIND Therapeutics, Inc., H1 2016 53 Diffuse Large B-Cell Lymphoma - Pipeline by Biocon Limited, H1 2016 54 Diffuse Large B-Cell Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H1 2016 55 Diffuse Large B-Cell Lymphoma - Pipeline by Bristol-Myers Squibb Company, H1 2016 56 Diffuse Large B-Cell Lymphoma - Pipeline by Celgene Corporation, H1 2016 57 Diffuse Large B-Cell Lymphoma - Pipeline by Cell>Point, L.L.C., H1 2016 58 Diffuse Large B-Cell Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H1 2016 59 Diffuse Large B-Cell Lymphoma - Pipeline by Constellation Pharmaceuticals, Inc., H1 2016 60 Diffuse Large B-Cell Lymphoma - Pipeline by CTI BioPharma Corp., H1 2016 61 Diffuse Large B-Cell Lymphoma - Pipeline by Curis, Inc., H1 2016 62 Diffuse Large B-Cell Lymphoma - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016 63 Diffuse Large B-Cell Lymphoma - Pipeline by eFFECTOR Therapeutics, Inc., H1 2016 64 Diffuse Large B-Cell Lymphoma - Pipeline by Eisai Co., Ltd., H1 2016 65 Diffuse Large B-Cell Lymphoma - Pipeline by EpiZyme, Inc., H1 2016 66 Diffuse Large B-Cell Lymphoma - Pipeline by Erytech Pharma SA, H1 2016 67 Diffuse Large B-Cell Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 68 Diffuse Large B-Cell Lymphoma - Pipeline by Genentech, Inc., H1 2016 69 Diffuse Large B-Cell Lymphoma - Pipeline by Genosco, H1 2016 70 Diffuse Large B-Cell Lymphoma - Pipeline by Gilead Sciences, Inc., H1 2016 71 Diffuse Large B-Cell Lymphoma - Pipeline by GlaxoSmithKline Plc, H1 2016 72 Diffuse Large B-Cell Lymphoma - Pipeline by Hutchison MediPharma Limited, H1 2016 73 Diffuse Large B-Cell Lymphoma - Pipeline by Idera Pharmaceuticals, Inc., H1 2016 74 Diffuse Large B-Cell Lymphoma - Pipeline by ImmunoGen, Inc., H1 2016 75 Diffuse Large B-Cell Lymphoma - Pipeline by Immunomedics, Inc., H1 2016 76 Diffuse Large B-Cell Lymphoma - Pipeline by Immunovaccine, Inc., H1 2016 77 Diffuse Large B-Cell Lymphoma - Pipeline by Incyte Corporation, H1 2016 78 Diffuse Large B-Cell Lymphoma - Pipeline by Inflection Biosciences Limited, H1 2016 79 Diffuse Large B-Cell Lymphoma - Pipeline by Johnson & Johnson, H1 2016 80 Diffuse Large B-Cell Lymphoma - Pipeline by Juno Therapeutics Inc., H1 2016 81 Diffuse Large B-Cell Lymphoma - Pipeline by Karus Therapeutics Limited, H1 2016 82 Diffuse Large B-Cell Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 83 Diffuse Large B-Cell Lymphoma - Pipeline by Kite Pharma, Inc., H1 2016 84 Diffuse Large B-Cell Lymphoma - Pipeline by Mabion SA, H1 2016 85 Diffuse Large B-Cell Lymphoma - Pipeline by mAbxience S.A., H1 2016 86 Diffuse Large B-Cell Lymphoma - Pipeline by MedImmune, LLC, H1 2016 87 Diffuse Large B-Cell Lymphoma - Pipeline by Medivation, Inc., H1 2016 88 Diffuse Large B-Cell Lymphoma - Pipeline by Merck & Co., Inc., H1 2016 89 Diffuse Large B-Cell Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 90 Diffuse Large B-Cell Lymphoma - Pipeline by Mirati Therapeutics Inc., H1 2016 91 Diffuse Large B-Cell Lymphoma - Pipeline by Mirna Therapeutics, Inc., H1 2016 92 Diffuse Large B-Cell Lymphoma - Pipeline by Molplex Ltd., H1 2016 93 Diffuse Large B-Cell Lymphoma - Pipeline by MorphoSys AG, H1 2016 94 Diffuse Large B-Cell Lymphoma - Pipeline by Neumedicines Inc., H1 2016 95 Diffuse Large B-Cell Lymphoma - Pipeline by Nimbus Therapeutics, LLC, H1 2016 96 Diffuse Large B-Cell Lymphoma - Pipeline by Nordic Nanovector ASA, H1 2016 97 Diffuse Large B-Cell Lymphoma - Pipeline by Novartis AG, H1 2016 98 Diffuse Large B-Cell Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 99 Diffuse Large B-Cell Lymphoma - Pipeline by Pfizer Inc., H1 2016 100 Diffuse Large B-Cell Lymphoma - Pipeline by Philogen S.p.A., H1 2016 101 Diffuse Large B-Cell Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H1 2016 102 Diffuse Large B-Cell Lymphoma - Pipeline by ProNAi Therapeutics, Inc., H1 2016 103 Diffuse Large B-Cell Lymphoma - Pipeline by RedHill Biopharma Ltd., H1 2016 104 Diffuse Large B-Cell Lymphoma - Pipeline by Respiratorius AB, H1 2016 105 Diffuse Large B-Cell Lymphoma - Pipeline by Rhizen Pharmaceuticals S.A., H1 2016 106 Diffuse Large B-Cell Lymphoma - Pipeline by Sandoz International GmbH, H1 2016 107 Diffuse Large B-Cell Lymphoma - Pipeline by Seattle Genetics, Inc., H1 2016 108 Diffuse Large B-Cell Lymphoma - Pipeline by Selvita S.A., H1 2016 109 Diffuse Large B-Cell Lymphoma - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016 110 Diffuse Large B-Cell Lymphoma - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 111 Diffuse Large B-Cell Lymphoma - Pipeline by TG Therapeutics, Inc., H1 2016 112 Assessment by Monotherapy Products, H1 2016 113 Assessment by Combination Products, H1 2016 114 Number of Products by Stage and Target, H1 2016 116 Number of Products by Stage and Mechanism of Action, H1 2016 121 Number of Products by Stage and Route of Administration, H1 2016 125 Number of Products by Stage and Molecule Type, H1 2016 127 Diffuse Large B-Cell Lymphoma Therapeutics - Recent Pipeline Updates, H1 2016 427 Diffuse Large B-Cell Lymphoma - Dormant Projects, H1 2016 722 Diffuse Large B-Cell Lymphoma - Dormant Projects (Contd..1), H1 2016 723 Diffuse Large B-Cell Lymphoma - Dormant Projects (Contd..2), H1 2016 724 Diffuse Large B-Cell Lymphoma - Discontinued Products, H1 2016 725 Diffuse Large B-Cell Lymphoma - Discontinued Products (Contd..1), H1 2016 726
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
